Real‐world evaluation of automated insulin delivery therapy in type 1 diabetes: A multicentre study across regional and metropolitan Queensland, Australia
Authors' conclusion
AID therapy significantly improves glycaemic control in adults with T1DM in both regional and metropolitan Australia. Our findings support the real-world effectiveness of AID systems and highlight their potential to bridge care gaps across diverse settings.
Study context
- Population
- Adults with T1D initiated on automated insulin delivery (AID) at three Australian hospital sites (Logan, metropolitan; Mackay and Townsville, regional)
- Participants
- 158 adults
- Exposure
- Before vs after AID initiation
- Outcome
- Change in HbA1c and continuous glucose monitoring (CGM) time-in-range (TIR) (3.9-10 mmol/L)
- Follow-up
- Up to 12 months
Methodological detailsretrospective audit, multicentre, real-world
- Retrospective audit
- Multicentre
- Real-world
Main finding
As reported in the abstract
follow-up
Follow-up vs Baseline: P < 0.0001 · Follow-up vs Baseline: P < 0.0001
- Achieved HbA1c <7% at follow-up
- 42.7%
- Achieved HbA1c <7.5% at follow-up
- 64.1%
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Baseline | Follow-up | P value |
|---|---|---|---|
| Time in hyperglycaemia (>13.9 mmol/L) · follow-upDeclined | 18.7% (SD 19.4%) | 8.4% (SD 9.31%) | P < 0.0001 |
Predictors of HbA1c reduction
- Higher baseline HbA1c a significant predictor of HbA1c reduction (multivariable regression)
- P < 0.0001
Consistency across AID system types and settings
- Improvements were consistent across AID system types and geographical settings
Original publication
Real‐world evaluation of automated insulin delivery therapy in type 1 diabetes: A multicentre study across regional and metropolitan Queensland, Australia. Diabetes Obes Metab. Published 28 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →